the Hospital del Sureste promotes improvements in the treatment of lymphoma non-Hodgkin’s
has celebrated a day to analyze the latest therapeutic in this field
Madrid, April 2012.- the Southeast Hospital has organized a day of update on Lymphoma non hodgkin (b) diffuse large cell (LBDCG) in which specialists in hematology have analysed the latest developments to improve survival in these patientsas well as new approaches in their diagnosis and treatment.
Experts gathered in the Madrid health centre have studied the recent discoveries in molecular and genetic patterns and their relationship to the effectiveness of the medical treatments available for this condition.
Diffuse large B-cell Lymphoma (LBDCG) is the most common of non Hodgkin Lymphomas and accounts for 30% of the cases diagnosed in our country.
Other issues discussed in the Hospital del Sureste have been the results of current methods and diagnostic criteria, as well as the effectiveness of newer drugs, even in the last phase of study, with a view to its clinical application. These innovative drugs attack cancer through their biology, heading towards specific molecular features to prevent malignant proliferation.
common protocol for the treatment
La Jornada, organized by the service of Hematology of the Hospital del Sureste, had the participation of speakers from the hospitals King Juan Carlos (Mostoles), Infanta Leonor (Vallecas), Tajo (Aranjuez), Infanta SofÃa (Alcobendas) and the Henares (Coslada), who are driving the development of a protocol for the treatment of these patients in new public hospitals of Madrid.
The aim is to share knowledge and clinical outcomes with a view to draw conclusions about the clinical management more suitable non hodgkin (b) diffuse large cell lymphomas.
